Update on Somatic Genomic Alterations in Follicular Cell-Derived Thyroid Cancers

Area of Science:

• Genomics
• Oncology
• Molecular Biology

Background:

• Advances in sequencing technologies (polymerase chain reaction-based, Sanger, massive parallel sequencing) over 40 years have enabled comprehensive genomic profiling of human cancers.
• These technological advancements have led to significant improvements in the clinical management of thyroid cancer patients.

Purpose of the Study:

• To review the landscape of somatic mutations in thyroid carcinomas originating from follicular cells.
• To discuss the clinical utility of molecular testing in managing differentiated, poorly differentiated, and anaplastic/undifferentiated thyroid carcinomas.

Main Methods:

• Review of genomic data from various sequencing platforms.
• Analysis of somatic mutation profiles in different subtypes of thyroid carcinoma.
• Evaluation of the role of molecular testing in clinical decision-making.

Main Results:

• Detailed discussion of somatic mutations across differentiated, poorly differentiated, and anaplastic/undifferentiated thyroid carcinomas.
• Highlighting the translation of genomic discoveries into diagnostic, prognostic, and therapeutic applications.
• Emphasis on the integration of molecular testing into patient care.

Conclusions:

• Genomic profiling has transformed the understanding and management of thyroid cancer.
• Molecular testing is indispensable for personalized diagnosis, prognosis, and treatment strategies.
• Continued research in cancer genomics will further enhance patient outcomes.